Stephen K. Doberstein, SVP & Chief Scientific Officer at NEKTAR THERAPEUTICS (NKTR), sold 396,323 shares at $24.98 ($11.5M) on 2017-11-06, disclosed to the SEC on 2017-11-08.
Open-market sale of $11.5M NKTR by SVP & Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $24.98 | 20,914 | $522K | 4.5% |
| 2 | $25.78 | 75,409 | $1.9M | 16.9% |
| 3 | $30.09 | 300,000 | $9.0M | 78.5% |
| Total | $29.00 avg | 396,323 | $11.5M | 100% |
| Filing → |
| NKTR | SELL | 2019-05-17 | $217K | — | Filing → |
| NKTR | SELL | 2019-02-21 | $281K | — | Filing → |
| NKTR | SELL | 2018-11-19 | $173K | — | Filing → |